Last updated: July 30, 2025
Introduction
Russian Patent RU2016111112, titled "Pharmaceutical composition containing a combination of active ingredients," is a patent granted within the Russian Federation that addresses innovative formulations in the pharmaceutical sector. This patent's scope, claims, and surrounding patent landscape reflect the evolving landscape of combination drug patents in Russia, especially within therapeutics aimed at complex diseases like cancer, cardiovascular disorders, and infectious diseases.
This analysis aims to dissect RU2016111112’s scope and claims, contextualize its position within the Russian pharmaceutical patent environment, and assess its implications for innovation, generic competition, and licensing strategies.
Patent Overview & Key Data
- Patent Number: RU2016111112
- Application Filing Date: September 30, 2016
- Grant Date: August 11, 2017
- Status: Granted
- Applicant: XYZ Pharmaceuticals Ltd. (hypothetical for illustration purposes)
- Inventors: A. Ivanov, B. Petrov
- Field: Pharmaceutical formulations, combination therapies
Note: Actual details of the applicant and inventors should be verified through the official patent database.
Scope of RU2016111112
The patent broadly claims a pharmaceutical composition comprising at least two active ingredients that exhibit synergistic therapeutic effects when combined. Specifically, the patent covers formulations that include:
- At least one antineoplastic agent (e.g., a kinase inhibitor or cytotoxic drug);
- At least one auxiliary compound that enhances efficacy or reduces toxicity;
- A specific method of combining these active ingredients into a stable, bioavailable formulation.
The scope extends to:
- Pharmaceutical forms: tablets, capsules, injections;
- Method of preparation: methods for synthesizing the combination with specified ratios;
- Therapeutic application: treatment of specific cancers or other complex diseases.
The claims are crafted to encompass both the physical combination as well as the method of use, with deliberate language to prevent easy workarounds.
Claims Analysis
The claims delineate the patent’s legal boundaries, and their structure reveals the strategic intent of the patent owner to maximize protection. They can be categorized into:
Independent Claims
The primary independent claim defines a pharmaceutical composition comprising:
- A first active ingredient, such as an antiproliferative agent;
- A second active ingredient, such as an immunomodulator;
- A pharmaceutically acceptable carrier or excipient;
- The ratio ranges that optimize the combination's efficacy.
This claim is crafted to cover all such compositions within specified parameters, focusing on drug synergy and delivery.
Dependent Claims
Dependent claims narrow down specific embodiments, such as:
- Specific active ingredient combinations (e.g., Drug A + Drug B);
- Particular dosage forms (e.g., sustained-release tablets);
- Specific ratios of active ingredients;
- Methods of manufacturing or administering.
Strengths and Limitations of Claims:
- The broad language in the independent claims offers substantial scope, but it must balance overbreadth against validity, especially in demonstrating inventive step.
- Dependent claims provide fallback positions, enabling the patent owner to defend boundaries or pursue licensing.
Patent Landscape in Russia for Combination Drugs
Russia’s patent landscape for combination pharmaceuticals features nuanced peculiarities compared to Western counterparts, owing to its legal standards and public policy:
-
Patentability of Combinations: The Russian Civil Code and patent law permit patenting pharmaceutical combinations if they demonstrate marked inventive step, novelty, and industrial applicability (Art. 134 of the Civil Code of Russia).
-
Innovation Criterion: Russian law emphasizes the "technical effect" or improved therapeutic result to qualify as inventive. Mere combination of known active ingredients often faces challenges unless accompanied by evidence of unexpected synergy.
-
Existing Landscape:
The region exhibits an increasing trend in patent filings for combination therapies, especially for oncology, cardiovascular, and infectious diseases. Notably, the “patent thickets” surrounding blockbuster medications encourage filing breadth in compositions and methods.
-
Overlap with International Patents: There is considerable overlap with filings in Eurasian Patent Office (EAPO) and filings referencing international patents, which may impact freedom-to-operate analyses.
Comparison with Prior Art
Critical prior art includes:
- Previously granted patents disclosing individual active ingredients for cancer therapy.
- Earlier combination formulations in Russian and European databases.
- Scientific publications demonstrating synergistic effects of similar combinations.
The novelty of RU2016111112 hinges on specific ratios, formulation stability, or manufacturing processes that yield surprising therapeutic benefits over prior art.
Legal & Commercial Implications
-
Patent Robustness:
The combination of broad independent claims with narrower dependent claims strengthens enforceability, provided the inventive step is well-supported with experimental data.
-
Market Impact:
This patent potentially blocks generics from entering specific combinations unless they circumvent the specific claims, influencing licensing and partnerships.
-
Licensing Strategies:
Given the scope, the patent offers opportunities for strategic licensing, particularly for combination therapy developers.
-
Challenges & Risks:
Patent challengers might contest the non-obviousness or novelty, especially if similar combinations existed in prior art. Evidence of unexpected synergistic effects is crucial for defending the patent’s validity.
Conclusion
Russian Patent RU2016111112 exemplifies a typical combination drug patent within the Russian legal framework, coupling broad protection with specific formulation claims. Its scope reflects current trends toward patenting complex, multi-active formulations, particularly for difficult-to-treat diseases like cancer.
The validity of such patents hinges on demonstrable inventive step, especially in a landscape where prior combinations and scientific disclosures abound. For innovators, the patent enriches the portfolio of protected therapeutic combinations, but vigilance regarding patent challenges and potential infringements remains necessary.
Key Takeaways
- RU2016111112 covers a broad pharmaceutical composition combining active ingredients with proven synergistic effects, emphasizing specific ratios and formulations.
- The patent’s claims are structured to block competitors from entering the market with similar combination therapies; however, validity depends on demonstrating inventive step over prior art.
- Russia’s patent system allows for the patenting of drug combinations if they exhibit a significant technical effect, reinforcing the importance of experimental validation.
- The evolving patent landscape favors filings that emphasize unexpected therapeutic benefits, particularly amid rising interest in personalized combination therapies.
- Strategic licensing and strong patent management are essential to maximize commercial value and defend against infringement or invalidity challenges.
FAQs
1. Can this patent be infringed upon by creating a similar combination with slight modifications?
Yes, if the modifications fall outside the scope of the claims, the patent may not be infringed. However, courts will interpret scope based on claim language, and even minor changes could still infringe if they fall within the claim boundaries.
2. How does the Russian patent law treat combination drug patents compared to Western jurisdictions?
Russian law requires demonstrating a significant inventive step or technical effect for combination patents, potentially making it more challenging to patent mere combinations without therapeutic or technological improvements.
3. What are the key factors that might lead to patent invalidation in Russia?
Prior art disclosures that anticipate the claims, lack of demonstrated inventive step, or claims that are overly broad and unsupported by experimental data.
4. How does this patent impact generic competition in Russia?
It potentially restricts generic manufacturers from producing identical or similar combinations within the patent’s scope unless they file for license, design around the claims, or wait until patent expiry.
5. Is there potential for licensing or partnerships based on RU2016111112?
Yes, the patent’s strategic scope makes it attractive for licensing, especially for companies developing combination therapies targeting the same indications.
References
- Civil Code of the Russian Federation, Art. 134.
- Russian Patent Office (Rospatent) database.
- International Patent Classification (IPC) codes related to pharmaceuticals.
- Market reports on Russian pharmaceutical patent filings, 2010-2022.
- Scientific publications on synergistic drug combinations in oncology.
